系统性脂质和葡萄糖调节在阿尔茨海默病小鼠模型中对认知功能和神经炎症产生差异性影响
Demos Kynigopoulos1, Eleni Fella1, Lucy Shahabian1
1Neuropathology Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Frontiers in neuroscience
|September 15, 2025
概括
代谢剂Alirocumab和Gliclazide改善了阿尔茨海默氏症患者的认知和突触功能.
科学领域:
- 神经科学是一个神经科学.
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 涉及突触功能障碍和认知衰退,越来越多的证据将系统代谢问题与其发展联系在一起.
- 调节周围脂质和葡萄糖代谢对阿尔茨海默氏症进展的影响仍然在很大程度上是未知的.
研究的目的:
- 在小鼠模型中研究阿利罗库马布 (PCSK9抑制剂) 和格利克拉 (硫氨酸urea) 对阿尔茨海默病进展的影响.
- 评估代谢干预在改变AD中神经退行和突触过程中的潜力.
主要方法:
- 慢性治疗5xFADADAD模型小鼠用阿利罗库马布或格利克拉齐德治疗五个月.
- 综合性评估包括行为测试,海马电生理学,ELISA,脂管学和阿迪波金 (adipokine) 分析.
主要成果:
- 阿利罗库马布增强了空间记忆,恢复了突触可塑性,并使突触标记正常化.
- 格利克拉减少了神经炎症,并保留了神经元/质标记物.
- 这两种药物都降低了粉样蛋白负担,调节了脂蛋白,并在脂肪组织中显示出明显的脂质重塑.
结论:
- 脂质和葡萄糖代谢的系统调节可以显著影响阿尔茨海默病中的神经退行和突触功能.
- 代谢干预表明作为阿尔茨海默病的治疗策略有希望,通过外周 - 中枢代谢通信进行调解.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825


